Ying Huang

“We began 2026 with strong momentum as we executed it commercially and continue to advance our pipeline. Legend is the largest standalone cell therapy company, anchored by Carvicti, our market-leading and profitable CAR-T therapy for multiple myeloma.”

“So, on your first question, we are planning and also we're committed to sequential growth throughout the year. That includes all four quarters of 2026.”

“The third quarter was marked by significant milestones that I will elaborate on momentarily. And we are looking forward to presenting new data at the Annual American Society of Hematology meeting in December.”

“We had quite an eventful second quarter as we made history with our long-term survival data at ASCO and achieved the most CAR-T sales ever during a single quarter.”

“During the first quarter we continued executing on our strategic priorities by increasing the number of global ATCs and patients treated with CARVYKTI in partnership with J&J, delivering operational efficiency and making continued investments.”